Not long ago before the clinical trial in pancreatic cancer starts, Pharmacyte Biotech Inc (OTCMKTS:PMCB) has announced some of the major milestones that it wishes to achieve.

Insights On Milestones

Pharmacyte is better known for offering world class live-cell encapsulation technology named Cell-in-a-Box, which is capable of treating diabetes and cancer. It’s planning to start Phase 2b clinical trial in pancreatic cancer to test the efficiency and safety of the cancer treatment provided by the company. The company has announced some milestones right before the beginning of the trial. Here are they-

  • The first trial is to finalize the design of the trial. The company wants to execute this trial under the guidance of world-class oncologists to ensure positive results without much supervision.
  • The recruitment of IND team is more of a need than milestone to ensure that Pharmacyte can submit its IND to authorities on time and review everything to avoid any last moment hassle.
  • It also plans to prepare a clinical protocol through its Contract Research Organization under the supervision of expert oncologists. It can be viewed as a recipe of how the trial will commence.
  • IND or Investigational New Drug application will be submitted to regulatory authorities before the initiation of the trial.

Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has decided to hold a meeting with its shareholders on October 29, 2015, to discuss a few important corporate governance requirements. The senior management of Stellar Biotechnologies expects the shareholders to approve these requirements. As per the reports, Stellar looks forward to listing itself on NASDAQ marketplace; hence, it wants to make sure everything falls in line before the listing process begins.

USANA Health Sciences, Inc. (NYSE:USNA) is one of the highly sought after health science companies. The company has been selected as one of the top 50 companies in Utah area. It’s the 8th consecutive time when USANA has made it to the Utah Business Fast 50 List. As per the reports, companies are shortlisted based on their growth rate in a particular year.